Compare Ascendis Pharma A/S (ASND) vs American States Water Company (AWR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs American States Water Company — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while American States Water Company trades at $84.94 (market cap $3.31B). The key difference: Ascendis Pharma A/S is far larger — about 5.4× American States Water Company's market cap, and American States Water Company pays a 2.39% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | AWR | |
|---|---|---|
Market Cap | $17.74B | $3.31B |
Sector | Health | Utilities |
52-Week High | $277.18 | $84.76 |
52-Week Low | $163.32 | $70.10 |
Enterprise Value | $18.11B | $4.22B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
American States Water (AWR) trades at $84.51, up 0.78% today, with a bullish technical outlook supported by moving averages and strong momentum indicators. The company reported solid 2025 results with $658M revenue and $130M net income, maintaining a robust 19.66% net margin. Recent news highlights its inclusion in TIME's America's Best Companies 2026 list and a completed $200M equity offering, reinforcing its stable utility model and 71-year dividend growth streak.
AWR offers defensive appeal with reliable dividends and infrastructure investments, but faces execution risks from regulatory approvals and interest rate sensitivity. Analyst consensus is mixed with 20% buy ratings, reflecting cautious optimism amid recent earnings misses. The stock's premium valuation (P/E 24.64) requires sustained growth to justify upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About American States Water Company
American States Water provides water and electric services to over one million people in the U.S. It also manages water and wastewater systems for various military bases under long-term privatization contracts.
Read more on AWR →
